WO2004047612A3 - Methods of therapy and diagnosis - Google Patents

Methods of therapy and diagnosis Download PDF

Info

Publication number
WO2004047612A3
WO2004047612A3 PCT/US2003/036971 US0336971W WO2004047612A3 WO 2004047612 A3 WO2004047612 A3 WO 2004047612A3 US 0336971 W US0336971 W US 0336971W WO 2004047612 A3 WO2004047612 A3 WO 2004047612A3
Authority
WO
WIPO (PCT)
Prior art keywords
tlr10
therapy
diagnosis
methods
polypeptides
Prior art date
Application number
PCT/US2003/036971
Other languages
French (fr)
Other versions
WO2004047612A2 (en
Inventor
Douglas Dedera
Peter C R Emtage
Original Assignee
Nuvelo Inc
Douglas Dedera
Peter C R Emtage
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/302,444 external-priority patent/US20040022786A1/en
Priority claimed from US10/327,491 external-priority patent/US20040023870A1/en
Application filed by Nuvelo Inc, Douglas Dedera, Peter C R Emtage filed Critical Nuvelo Inc
Priority to CA002506356A priority Critical patent/CA2506356A1/en
Priority to EP03786850A priority patent/EP1567863A4/en
Priority to AU2003295649A priority patent/AU2003295649A1/en
Publication of WO2004047612A2 publication Critical patent/WO2004047612A2/en
Publication of WO2004047612A3 publication Critical patent/WO2004047612A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Targeting therapy using TLR10 polypeptides, nucleic acids encoding for TLR10 polypeptides, anti-TLR10 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the TLR10 protein. Methods of therapy and diagnosis of disorders associated with TLR10 protein-expressing cells are described.
PCT/US2003/036971 2002-11-22 2003-11-19 Methods of therapy and diagnosis WO2004047612A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002506356A CA2506356A1 (en) 2002-11-22 2003-11-19 Methods of therapy and diagnosis
EP03786850A EP1567863A4 (en) 2002-11-22 2003-11-19 Methods of therapy and diagnosis
AU2003295649A AU2003295649A1 (en) 2002-11-22 2003-11-19 Methods of therapy and diagnosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/302,444 US20040022786A1 (en) 2000-01-21 2002-11-22 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US10/302,444 2002-11-22
US10/327,491 2002-12-19
US10/327,491 US20040023870A1 (en) 2000-01-21 2002-12-19 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US64122203A 2003-08-13 2003-08-13
US10/641,222 2003-08-13

Publications (2)

Publication Number Publication Date
WO2004047612A2 WO2004047612A2 (en) 2004-06-10
WO2004047612A3 true WO2004047612A3 (en) 2005-04-14

Family

ID=32397926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036971 WO2004047612A2 (en) 2002-11-22 2003-11-19 Methods of therapy and diagnosis

Country Status (4)

Country Link
EP (1) EP1567863A4 (en)
AU (1) AU2003295649A1 (en)
CA (1) CA2506356A1 (en)
WO (1) WO2004047612A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568526C (en) 2004-07-09 2015-11-03 Schering Aktiengesellschaft Combination therapy with radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
RU2401661C9 (en) * 2004-07-20 2011-01-27 Шеринг Корпорейшн Induction of apoptosis in tumour cells, expressing toll-like receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1887014E (en) * 1997-10-17 2010-07-05 Genentech Inc Human toll homologues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 2 August 1999 (1999-08-02), GODDARD ET AL.: "Human toll protein PRO358", XP002999283, Database accession no. AAY05868 *
DATABASE GENBANK [online] 27 March 2001 (2001-03-27), CHUANG ET AL.: "Homo sapiens too-like receptor 10 mRNA, complete cds", XP002999281, accession no. EMBL Database accession no. AF296673 *
DATABASE GENBANK [online] 5 April 2000 (2000-04-05), BAKER ET AL.: "Membrane-bound protein PRO358", XP002999284, Database accession no. AAY66644 *
DATABASE GENESEQ [online] 26 March 2002 (2002-03-26), HARDIMAN ET AL.: "Human DNAS toll like receptor (DTLR) 8 cDNA #3", XP002999282, Database accession no. AAD26299 *
See also references of EP1567863A4 *

Also Published As

Publication number Publication date
WO2004047612A2 (en) 2004-06-10
EP1567863A2 (en) 2005-08-31
AU2003295649A1 (en) 2004-06-18
EP1567863A4 (en) 2007-10-03
CA2506356A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
EP1137658A4 (en) METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
WO2002099055A3 (en) Cips as modifiers of the p53 pathway and method of use
WO2005056606A3 (en) Optimized antibodies that target the epidermal growth factor receptor
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
EP1409509A4 (en) Antisense modulation of c-reactive protein expression
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2006109044A3 (en) Selective modulation of tumour necrosis factor receptors in therapy
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
WO2004051269A3 (en) Ciz1 replication protein
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
WO2004047758A3 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
WO2004069860A3 (en) Isg15-conjugated proteins
WO2004047612A3 (en) Methods of therapy and diagnosis
WO2004053061A3 (en) Methods of therapy and diagnosis using targeting of cells that express lax
WO2005060375A3 (en) Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein
WO2001049832A3 (en) Transduction of recombinases for inducible gene targeting
WO2004049917A3 (en) Methods of therapy and diagnosis using targeting of cells that express ly-9
AU2003237493A1 (en) Methods for treating diseases or conditions with peptide constructs
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
WO2003032899A3 (en) Methods and materials for targeting and affecting selected cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003295649

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2506356

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003786850

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003786850

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP